Relmada Therapeutics To Present Data From Its REL-1017 And Psilocybin Programs At The 36Th European College Of Neuropsychopharmacology Congress
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics is set to present data from its REL-1017 and Psilocybin programs at the 36th European College of Neuropsychopharmacology Congress.
October 06, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Relmada Therapeutics' presentation at the European College of Neuropsychopharmacology Congress could potentially influence its stock price depending on the data shared.
The presentation of data from Relmada Therapeutics' REL-1017 and Psilocybin programs could potentially influence investor sentiment and thus the stock price. The impact will depend on the perceived success or failure of the presented data.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100